1. Expression of the human cancer/testis antigen NY-SAR-35 is activated by CpG island hypomethylation.
- Author
-
Park JH, Song MH, Lee CH, Lee MK, Park YM, Old L, and Lee SY
- Subjects
- Azacitidine analogs & derivatives, Azacitidine pharmacology, Base Sequence, Biotechnology, Cell Line, Tumor, Cloning, Molecular, DNA Methylation, DNA Primers genetics, Decitabine, Female, Gene Expression drug effects, Humans, Male, Promoter Regions, Genetic, RNA, Neoplasm genetics, Transfection, Antigens, Neoplasm genetics, CpG Islands, Testis immunology
- Abstract
The novel cancer/testis antigen gene, NY-SAR-35, is expressed exclusively in normal testis and in various histological types of tumor. However, the NY-SAR-35 gene expression is observed to be aberrant in several cancer cell lines and tissues. The analysis of methylation status of the NY-SAR-35 gene promoter in various cancer cell lines showed that its expression was related to methylation of the promoter region. Treatment of human cancer cell lines with the demethylating agent 5-aza-2'-deoxycytidine activated the expression of the NY-SAR-35 gene. In addition, transfection experiments on various fragments of the CpG-rich gene promoter indicate that in vitro methylation of the NY-SAR-35 gene promoter results in the loss of promoter activity. The expression of NY-SAR-35 is therefore activated by hypomethylation of the CpG island in the gene promoter.
- Published
- 2011
- Full Text
- View/download PDF